FTC Settles With CVS Over Insulin Price Manipulation
The FTC reached a proposed settlement with CVS Caremark over allegations its PBM artificially inflated insulin prices and blocked patient access.
Robert Kim
Technology & Innovation
Medical TechnologyAI in MedicineDigital HealthBiomedical Engineering
About Robert
Robert Kim is a biomedical engineer at the University of Hawaii Cancer Center with a focus on medical device development and computational approaches to clinical data. He covers medical technology, AI in medicine, digital health platforms, and telemedicine advances for Hawaii Medical Journal.
Articles by Robert
FDA Approves Kresladi Gene Therapy for Rare LAD-1 Disease
The FDA has approved Rocket Pharma's Kresladi for LAD-1, a rare immunodeficiency affecting roughly 25 US patients annually, marking a gene therapy milestone.
How to Become a More Compassionate Clinical Leader
Discover evidence-based principles of compassionate leadership in healthcare, addressing physician burnout and workforce retention in clinical settings.
Trump Drug Pricing Flaw & Gilead Deal: What to Know
A structural gap in Trump's most-favored nation drug pricing framework raises doubts, while Gilead Sciences makes a major autoimmune therapeutics acquisition.
Apogee's Zumilokibart Shows Promise for Eczema in 2026
Apogee Therapeutics' zumilokibart showed skin clearance and itch relief for atopic dermatitis with less frequent injections in mid-stage trial results.
CMS Chief Tempers TrumpRx Expectations in 2026
CMS administrator Chris Klomp clarified TrumpRx targets the uninsured, not most Americans, countering President Trump's broader claims about the drug discount platform.
ARPA-H Develops FDA-Authorized AI Agents for Clinical Use
ARPA-H is advancing FDA-authorized AI clinical tools in 2026, pairing federal research funding with mandatory clinical trial validation and deployment pathways.
Tourette Syndrome: Why Media Distortion Harms Clinical Care
When media reduces Tourette syndrome to debates about offense, patients face real clinical consequences. Here's what the coverage gets wrong.
Doctors Need Humility to Combat Health Misinformation
Experts at the Nuffield Trust Summit say clinicians must respond to patient-sourced misinformation with professional humility, not dismissal.
FDA Targets Telehealth GLP-1 Compounders in 2026 Crackdown
FDA has warned 70+ telehealth companies over compounded GLP-1 drugs, with scrutiny now extending to affiliated medical groups and prescribing networks.
Big Pharma Antibiotic Pipelines Shrink 35% in Five Years
Major drugmakers reduced antimicrobial development programs from 92 to 60 over five years, raising alarm over the global response to antibiotic resistance.